Enovis announced its strategic partnership with Ossium Health to distribute OssiGraft and OssiGraft Prime—cryopreserved viable bone matrix (VBX) allografts—through Enovis’ extensive sales network.
The allografts consist of 100% viable bone in a demineralization-free solution, with 80% cancellous bone. This composition optimizes bone healing, as research suggests the cancellous bone enables faster revascularization in two weeks, compared to the two-month process required for cortical bone. With an average donor age of 35, OssiGraft and OssiGraft Prime deliver biological vitality, allowing them to compete with competitors in efficacy.
The Enovis product portfolio provides a comprehensive selection of engineered solutions, such as the DynaNail TTC Fusion System, which utilizes sustained dynamic compression technology. The combination of structural reinforcement and biological foundation can support more successful fusion.
“Our newly forged alliance with Ossium Health enriches our portfolio with invaluable allograft solutions,” said Gary Justak, President and General Manager of Enovis Foot & Ankle. “By integrating these premium grafts into our distribution network, we are expanding our capacity to provide surgeons with advanced products that redefine surgical results and elevate patient care.”
Enovis announced its strategic partnership with Ossium Health to distribute OssiGraft and OssiGraft Prime—cryopreserved viable bone matrix (VBX) allografts—through Enovis’ extensive sales network.
The allografts consist of 100% viable bone in a demineralization-free solution, with 80% cancellous bone. This composition optimizes bone healing,...
Enovis announced its strategic partnership with Ossium Health to distribute OssiGraft and OssiGraft Prime—cryopreserved viable bone matrix (VBX) allografts—through Enovis’ extensive sales network.
The allografts consist of 100% viable bone in a demineralization-free solution, with 80% cancellous bone. This composition optimizes bone healing, as research suggests the cancellous bone enables faster revascularization in two weeks, compared to the two-month process required for cortical bone. With an average donor age of 35, OssiGraft and OssiGraft Prime deliver biological vitality, allowing them to compete with competitors in efficacy.
The Enovis product portfolio provides a comprehensive selection of engineered solutions, such as the DynaNail TTC Fusion System, which utilizes sustained dynamic compression technology. The combination of structural reinforcement and biological foundation can support more successful fusion.
“Our newly forged alliance with Ossium Health enriches our portfolio with invaluable allograft solutions,” said Gary Justak, President and General Manager of Enovis Foot & Ankle. “By integrating these premium grafts into our distribution network, we are expanding our capacity to provide surgeons with advanced products that redefine surgical results and elevate patient care.”
Copy to clipboard 
